KR101008314B1 - Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도 - Google Patents

Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도 Download PDF

Info

Publication number
KR101008314B1
KR101008314B1 KR1020080028576A KR20080028576A KR101008314B1 KR 101008314 B1 KR101008314 B1 KR 101008314B1 KR 1020080028576 A KR1020080028576 A KR 1020080028576A KR 20080028576 A KR20080028576 A KR 20080028576A KR 101008314 B1 KR101008314 B1 KR 101008314B1
Authority
KR
South Korea
Prior art keywords
cancer
ovarian cancer
expression
antibody
cells
Prior art date
Application number
KR1020080028576A
Other languages
English (en)
Korean (ko)
Other versions
KR20090103163A (ko
Inventor
이제호
황재령
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Priority to KR1020080028576A priority Critical patent/KR101008314B1/ko
Priority to PCT/KR2009/001576 priority patent/WO2009120039A2/fr
Publication of KR20090103163A publication Critical patent/KR20090103163A/ko
Application granted granted Critical
Publication of KR101008314B1 publication Critical patent/KR101008314B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020080028576A 2008-03-27 2008-03-27 Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도 KR101008314B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020080028576A KR101008314B1 (ko) 2008-03-27 2008-03-27 Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도
PCT/KR2009/001576 WO2009120039A2 (fr) 2008-03-27 2009-03-27 Utilisation de cd9 en tant que protéine cible afin de développer un médicament anticancéreux pour les tumeurs solides surexprimant cd9

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080028576A KR101008314B1 (ko) 2008-03-27 2008-03-27 Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도

Publications (2)

Publication Number Publication Date
KR20090103163A KR20090103163A (ko) 2009-10-01
KR101008314B1 true KR101008314B1 (ko) 2011-01-14

Family

ID=41114472

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080028576A KR101008314B1 (ko) 2008-03-27 2008-03-27 Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도

Country Status (2)

Country Link
KR (1) KR101008314B1 (fr)
WO (1) WO2009120039A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009157623A1 (fr) * 2008-06-25 2009-12-30 Korea Research Institute Of Bioscience And Biotechnology Anticorps humains spécifiques de cd9
WO2017026694A1 (fr) * 2015-08-11 2017-02-16 영남대학교 산학협력단 Composition pharmaceutique pour prévenir ou traiter des maladies oculaires, contenant en tant que principe actif un anticorps contre le cd9
EP3400245A1 (fr) 2016-01-08 2018-11-14 Aimm Therapeutics B.V. Anticorps anti-cd9 thérapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007685A2 (fr) * 2002-07-12 2004-01-22 The University Of Tennessee Research Foundation Procedes pour modifier le comportement des cellules exprimant cd9

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Actas Dermosifiliogr.(제96권, 제1호, 제30-36면, 2005년)*
Human pathology(제35권, 제8호, 제1014-1021면, 2005년)*

Also Published As

Publication number Publication date
KR20090103163A (ko) 2009-10-01
WO2009120039A2 (fr) 2009-10-01
WO2009120039A3 (fr) 2009-11-26

Similar Documents

Publication Publication Date Title
US11203641B2 (en) Screening for anti-cancer compounds using netrin-1 activity
Garcia-Rostan et al. β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis
EP2547698B1 (fr) Procédés de détermination de la sensibilité de tumeurs à des inhibiteurs de la tyrosine kinase
US7473561B2 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
AU2015206603B2 (en) Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US20020187502A1 (en) Method of detection and treatment of colon cancer
KR101549245B1 (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
KR102056137B1 (ko) 암의 검출 방법
WO2002054940A9 (fr) Proteine morphogenetique osseuse 2 (bmp-2) utilisee dans le traitement et le diagnostic du cancer
KR102056654B1 (ko) 암의 검출 방법
KR20150008926A (ko) 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
KR101560843B1 (ko) 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
KR20070049602A (ko) Ｈａｕｓｐ-ｍｄｍ2 상호작용 및 이의 용도
WO2019157495A2 (fr) Procédés de prévention et/ou de traitement de conditions de perte osseuse par modulation de l'irisine
KR20070091602A (ko) ｐ53-의존성 및 비의존성 종양 억제 매개체로서의ＡＲＦ-ＢＰ1 및 그의 용도
KR101008314B1 (ko) Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도
CA2568806C (fr) Procedes de detection et de traitement du cancer
KR101137019B1 (ko) 신규한 ｇｐｃｒ 단백질 및 이의 용도
ES2337696T3 (es) Metodos para aumentar la eficacia de la terapia contra el cancer.
US7683159B2 (en) Tenascin-W compositions and uses thereof
KR101776864B1 (ko) Npffr2 억제제를 유효성분으로 포함하는 암 전이 억제 및 암 치료용 조성물
KR20140144934A (ko) Ｃｔｈｒｃ１의 발현 및 활성 억제제를 유효성분으로 포함하는 췌장암 치료 및 전이억제용 조성물
Akhmedkhanov et al. BIOLOGY–PROGNOSTIC FACTORS
Wen Biological function of the MUC1 cytoplasmic tail in human pancreatic cancer
Degen Tenascins: prominent molecules in tumor stroma

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140106

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee